Equillium (EQ) Other Non-Current Assets (2019 - 2026)
Equillium (EQ) posted quarterly Other Non-Current Assets of $27000.0 for Q1 2026, little changed quarter-over-quarter from $27000.0 in Q4 2025.
Equillium (EQ) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Equillium (EQ) has reported Other Non-Current Assets for 8 consecutive years, with $27000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed N/A year-over-year to $27000.0; the TTM figure through Mar 2026 stood at $27000.0 (changed N/A YoY), while the FY2025 annual figure was $27000.0, changed N/A from the prior year.
- Other Non-Current Assets was little changed at $27000.0 in Q1 2026 per EQ's latest filing, from $27000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $145000.0 in Q1 2022 and bottomed at $27000.0 in Q4 2025.
- Historically, Other Non-Current Assets has averaged $79153.8 across 5 years, with a median of $79000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 611.76% — and 2024, when it plunged 43.04%.
- Equillium's Other Non-Current Assets stood at $104000.0 in 2022, then plunged by 32.69% to $70000.0 in 2023, then tumbled by 35.71% to $45000.0 in 2024, then sank by 40.0% to $27000.0 in 2025, then changed by 0.0% to $27000.0 in 2026.
- Business Quant data shows EQ's Other Non-Current Assets at $27000.0 in Q1 2026, $27000.0 in Q4 2025, and $45000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 27,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Mar 31, 2024 | 62,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | 79,000.00 |
| Jun 30, 2023 | 87,000.00 |
| Mar 31, 2023 | 96,000.00 |
| Dec 31, 2022 | 104,000.00 |
| Sep 30, 2022 | 113,000.00 |
| Jun 30, 2022 | 121,000.00 |
| Mar 31, 2022 | 145,000.00 |
| Dec 31, 2021 | 153,000.00 |
| Sep 30, 2021 | 57,000.00 |
| Jun 30, 2021 | 17,000.00 |
| Dec 31, 2020 | 15,000.00 |
| Dec 31, 2019 | 15,000.00 |
| Sep 30, 2019 | 15,000.00 |